Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.

Abstract

AIMS:

This study aimed to clarify the differences in how sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1Ra) influence kidney function in Japanese patients with type 2 diabetes mellitus (T2DM).

METHODS:

We retrospectively built two databases of patients with T2DM who visited the clinics of members of Kanagawa Physicians Association. We defined the renal composite outcome as either progression of albuminuria status and/or > 15% deterioration in estimated glomerular filtration rate (eGFR) per year. We used propensity score matching to compare patient outcomes after SGLT2i and GLP1Ra treatments.

RESULTS:

The incidence of renal composite outcomes was significantly lower in SGLT2i-treated patients than in GLP1Ra-treated patients (n = 15[11%] and n = 27[20%], respectively, P = 0.001). Annual eGFR changes (mL/min/1.73 m2/year) between the two groups differed significantly (-1.8 [95 %CI, -2.7, -0.9] in SGLT2i-treated patients and - 3.4 [95 %CI, -4.6, -2.2] in GLP1Ra-treated patients, P = 0.0049). The urine albumin-to-creatinine ratio changed owing to a significant interaction between the presence or absence of a decrease in systolic blood pressure and the difference in treatments (P < 0.04).

CONCLUSION:

Renal composite outcome incidence was lower in SGLT2i-treated patients than in GLP1Ra-treated patients.

• Authors: Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Hiroyuki Sakai, Takayuki Furuki, Keiichi Chin, Moritsugu Kimura, Nobumichi Saito, Tomohiko Kanaoka, Togo Aoyama, Tomoya Umezono, Shun Ito, Daisuke Suzuki, Hiroshi Takeda, Fuyuki Minagawa, Hisakazu Degawa, Hideo Machimura, Toshimasa Hishiki, Shinichi Umezawa, Hidetoshi Shimura, Shinichi Nakajima, Hareaki Yamamoto, Kazuyoshi Sato, Masaaki Miyakawa, Yasuo Terauchi, Kouichi Tamura, Akira Kanamori
• Journal: Diabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 185 Pg. 109231 (Mar 2022) ISSN: 1872-8227 [Electronic] Ireland
• PMID: 35131376 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Elsevier B.V. All rights reserved.

Chemical References

• Glucagon-Like Peptide-1 Receptor
• Hypoglycemic Agents
• Sodium-Glucose Transporter 2 Inhibitors
• Symporters
• Glucagon-Like Peptide 1
• Sodium
• Glucose

Topics

• Diabetes Mellitus, Type 2
• Female
• Glucagon-Like Peptide 1
• Glucagon-Like Peptide-1 Receptor (agonists)
• Glucose
• Humans
• Hypoglycemic Agents (therapeutic use)
• Kidney
• Male
• Retrospective Studies
• Sodium
• Sodium-Glucose Transporter 2 Inhibitors (pharmacology)
• Symporters